IQVIA and Medera partner on cardiac gene therapy development
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
IQVIA and Medera to Advance Cardiac Gene Therapy and Human-Based Drug Discovery
August 4, 2026 4:15 PM EDTRESEARCH TRIANGLE PARK, N.C. and BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- IQVIA (NYSE: IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, and Medera Inc. (Medera), a clinical-stage biopharmaceutical company pioneering next-generation therapeutics for cardiovascular disease, today announced a strategic collaboration to... More
